扶正中药逆转TLR4过表达乳腺癌紫杉醇耐药的机制

doi:10.3969/j.issn.2095-9400.2019.11.008

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (2083 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the mechanism of Fuzheng Chinese medicine combined with paclitaxel against TLR4 over-expressing breast cancer, and to confirm the sensitization effect of traditional Chinese medicine combined with chemotherapy for TLR4 over-expressed breast cancer MDA-MB-231 so as to select specific tumor phenotype for combination of traditional Chinese and western medicine. The target provides drug intervention to provide basic data. Methods: MTT assay was used to detect the proliferation inhibition effect of Fuzheng Chinese medicine, paclitaxel and two drugs on breast cancer cell lines T47D and MDA-MB-231. The apoptosis rate was detected by flow cytometry. Expression of the apoptosis related protein and TLR4/NF-kB signaling pathway-associated proteins was detected by Western blotting technology. Results: Fuzheng Chinese medicine and paclitaxel had synergistic effect in the treatment of MDA-MB-231 cell line; Fuzheng Chinese medicine assisted paclitaxel to induce apoptosis of MDA-MB-231 cell line (P<0.05); combined with Chinese medicine and paclitaxel, MDA-MB-231 Cell line TLR4/NF-kB signaling pathway was inhibited (P<0.05). Conclusion: In MDA-MB-231 cell line, Fuzheng Chinese medicine can increase cell apoptosis by inhibiting TLR4/NF-kB signaling pathway, thereby increasing the cell proliferation inhibition effect of paclitaxel on MDA-MB-231 breast cancer cell line and reversing paclitaxel-resistance in breast cancer.

Key words： Fuzheng Chinese medicine paclitaxel drug resistance breast cancer cell line TLR4/NF-kB signaling pathway

Received: 24 May 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xiangjian
	ZHANG Xinxin
	MA Haiguang
	HU Xiaoqing

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2019.11.008 OR https://xb.wmu.edu.cn/EN/Y2019/V49/I11/826

[1] FAN L, STRASSER-WEIPPL K, LI J J, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-289.
[2] JIA L, LIN H, OPPENHEIM J, et al. US National Cancer Institute-China Collaborative Studies on Chinese Medicine and Cancer[J]. J Natl Cancer Inst Monogr, 2017, 2017(52): 58-61.
[3] MENG H, PENG N, YU M, et al. Treatment of triple-negative breast cancer with Chinese herbal medicine: A prospective cohort study protocol[J]. Medicine (Baltimore), 2017, 96(44): e8408.
[4] WANG X, FANG G, PANG Y. Chinese Medicines in the Treatment of Prostate Cancer: From Formulas to Extracts and Compounds[J]. Nutrients, 2018, 10(3): E283.
[5] LOU J S, YAO P, TSIM K W K. Cancer treatment by using traditional Chinese medicine: probing active compounds in anti-multidrug resistance during drug therapy[J]. Curr Med Chem, 2018, 25(38): 5128-5141.
[6] 韩飞, 幸仁汇, 陈琳琦, 等. 中药抗细菌耐药性的研究进展[J]. 中国中药杂志, 2016, 41(5): 813-817.
[7] HUANG B, ZHAO J, LI H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance[J]. Cancer Res, 2005, 65(12): 5009-5014.
[8] 吕宝军, 张红雨, 王晓鸿, 等. 乳腺癌组织TLR4蛋白表达及与细胞凋亡和增殖的关系[J]. 中华普通外科学文献(电子版), 2011, 5(3): 211-213.
[9] KELLY M G, ALVERO A B, CHEN R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer[J]. Cancer Res, 2006, 66(7): 3859-3868.
[10] WU J, GUAN M, WONG P F, et al. Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway[J]. Food Chem Toxicol, 2012, 50(9): 3019-3024.
[11] RAJPUT S, VOLK-DRAPER L D, RAN S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer[J].Mol Cancer Ther, 2013, 12(8): 1676-1687.
[12] TANIMURA N, SAITOH S, MATSUMOTO F, et al. Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling[J]. Biochem Biophys Res Commun, 2008, 368(1): 94-99.
[13] 薛晓红, 江科, 李琼, 等. 乳腺癌患者治疗前后血清VEGF动态变化及乳癌术后方的干预作用[J]. 上海中医药杂志, 2011, 45(6): 46-48.
[14] 薛晓红, 刘胜, 杨新伟, 等. 乳宁冲剂及拆方对裸鼠移植瘤生长及肺转移的影响[J]. 上海中医药杂志, 2005, 39(7): 45-47.
[15] 阙华发, 陈红风, 高尚璞, 等. 乳宁II号防治乳腺癌MDA-MB-435裸鼠移植瘤生长转移作用及其抑制血管生成的机制研究[J]. 中国中医基础医学杂志, 2007, 13(8): 592-594.
[16] 刘玲琳, 刘胜. 乳移平配伍肺经引经药桔梗抗乳腺癌肺转移作用及机制的实验研究[J]. 上海中医药杂志, 2010, 44(10): 61-65.
[17] 姜华, 张艳, 王辰. 益气活血复方含药血清对人脐静脉内皮细胞TLR4及其下游髓样分化因子88、肿瘤坏死因子受体相关因子-6表达的影响[J]. 中国中西医结合杂志, 2010, 30(5): 519-522.
[18] 张彩霞, 江滨, 张亚杰, 等. 国内外文献对白术内酯Ⅱ抑制肿瘤细胞作用的浓度差异原因分析[J]. 中医药导报, 2017, 23(20): 30-32.
[19] ECKSTEIN-LUDWIG U, WEBB R J, VAN GOETHEM I D,
et al. Artemisinins target the SERCA of Plasmodium falci-parum[J]. Nature, 2003, 424(6951): 957-961.
[20] ARUMUGAM A, ABDULL RAZIS A F. Apoptosis as a mechanism of the cancer chemopreventive activity of glucosinolates: A review[J]. Asian Pac J Cancer Prev, 2018, 19(6): 1439-1448.